Postmenopausal Osteoporosis Treatment Market Size, Growth, Trends | Report 2023-2032
The global postmenopausal osteoporosis treatment market was valued at USD 12.6 billion in 2022 and it is predicted to surpass around USD 18.77 billion by 2032 with a CAGR of 4.07% from 2023 to 2032.
Menopause is the most common cause of osteoporosis, and the world is witnessing rise in burden of disease in postmenopausal women which is the key factor driving the market. According to an article published in March 2021, around 33.1% of postmenopausal women were affected with the disease and it is estimated to increase in prevalence to 50% in coming years. International Menopause Society (IMS) estimates 1 in 3 women above 50 years old report fractures due to osteoporosis. Moreover, rising geriatric population and lifestyle changes such has sedentary lifestyle, high alcohol consumption, unhealthy eating habits are impacting menstruating period of female and increasing risk of disease.
Report Scope of the postmenopausal osteoporosis treatment Market
| Report Coverage | Details |
| Market Size in 2022 | USD 12.6 billion |
| Revenue Forecast by 2032 | USD 18.77 billion |
| Growth rate from 2023 to 2032 | CAGR of 4.07% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Covered | Teva Pharmaceuticals Industries Ltd., Pfizer Inc., Merck & Co., Novartis AG, Eli Lilly and Company., AbbVie (Allergan plc.), Cipla Inc, Amgen Inc., and F. Hoffmann-La Roche Ltd amongst others |
Government and private organizations are actively taking initiatives to raise the awareness about the condition in society and fueling the market growth. Every year October 18 and October 20 are dedicated as World Menopause Day and World Osteoporosis Day, respectively to highlight the challenges of postmenopausal osteoporosis symptoms and related treatment for management of disease. Moreover, in January 2021, pan-Asia Pacific clinical practice standards were launched by Asia Pacific Consortium on Osteoporosis (APCO) to screen, diagnose, and management of disease. All these aforementioned factors are increasing the awareness and driving the postmenopausal osteoporosis treatment market.
Postmenopausal osteoporosis treatment market is segmented by drug type as:
The space has presence of medications such as bisphosphonates, vitamin D3 derivatives, selective estrogen receptor modulator (SERM), hormone replacement therapy and parathyroid hormone therapy that help to promote bone growth & stability and prevent bone from breaking down.
According to the new guidelines, patients at a very high risk of fracture should be prescribed denosumab, abaloparatide, teriparatide, romosozumab, and zoledronate as initial therapy. Postmenopausal patients diagnosed with osteoporosis, but not at very high risk of fracture, should be considered high-risk patients and be prescribed denosumab, alendronate, risedronate, and zoledronate. The inclusion of newly approved products, such as Evenity, in the revised treatment guidelines is likely to boost market growth. There are several drugs under clinical investigation, which are expected to be launched in the coming years, thereby creating lucrative opportunities for market growth. For instance, Gedeon Richter Plc’s drug candidate RGB-14-P is under phase 3 clinical trial for postmenopausal women with osteoporosis.
Major players are employing strategies such as new product launches, expansion, mergers & acquisitions, licensing partnerships, and co-development deals which fueling the market growth. For instance, in July 2022, Japanese firm Chugai Pharmaceutical Co., Ltd. launched vitamin D3 derivative drug Edirol (eldecalcitol) for postmenopausal women with disease in China.
postmenopausal osteoporosis treatment Market Segmentations:
| By Drugs Type | By Distribution Channel |
|
Bisphosphonates Vitamin D3 Derivative Estrogen agonist/antagonist Hormone Replacement Therapy Parathyroid Hormone Therapy Others |
Hospital pharmacies Retail pharmacies Others |
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Postmenopausal Osteoporosis Treatment Market
5.1. COVID-19 Landscape: Postmenopausal Osteoporosis Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Postmenopausal Osteoporosis Treatment Market, By Drugs Type
8.1. Postmenopausal Osteoporosis Treatment Market, by Drugs Type, 2023-2032
8.1.1. Bisphosphonates
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Vitamin D3 Derivative
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Estrogen agonist/antagonist
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Hormone Replacement Therapy
8.1.4.1. Market Revenue and Forecast (2020-2032)
8.1.5. Parathyroid Hormone Therapy
8.1.5.1. Market Revenue and Forecast (2020-2032)
8.1.6. Others
8.1.6.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Postmenopausal Osteoporosis Treatment Market, By Distribution Channel
9.1. Postmenopausal Osteoporosis Treatment Market, by Distribution Channel, 2023-2032
9.1.1. Hospital pharmacies
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Retail pharmacies
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Others
9.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Postmenopausal Osteoporosis Treatment Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Drugs Type (2020-2032)
10.1.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Drugs Type (2020-2032)
10.1.3.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Drugs Type (2020-2032)
10.1.4.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Drugs Type (2020-2032)
10.2.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Drugs Type (2020-2032)
10.2.3.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Drugs Type (2020-2032)
10.2.4.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Drugs Type (2020-2032)
10.2.5.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Drugs Type (2020-2032)
10.2.6.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Drugs Type (2020-2032)
10.3.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Drugs Type (2020-2032)
10.3.3.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Drugs Type (2020-2032)
10.3.4.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Drugs Type (2020-2032)
10.3.5.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Drugs Type (2020-2032)
10.3.6.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Drugs Type (2020-2032)
10.4.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Drugs Type (2020-2032)
10.4.3.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Drugs Type (2020-2032)
10.4.4.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Drugs Type (2020-2032)
10.4.5.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Drugs Type (2020-2032)
10.4.6.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Drugs Type (2020-2032)
10.5.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Drugs Type (2020-2032)
10.5.3.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Drugs Type (2020-2032)
10.5.4.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
Chapter 11. Company Profiles
11.1. Teva Pharmaceuticals Industries Ltd.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Pfizer Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Merck & Co.
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Novartis AG
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. LTE Scientific
11.5. Eli Lilly and Company.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. AbbVie (Allergan plc.)
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Cipla Inc, Amgen Inc.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. F. Hoffmann-La Roche Ltd
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. others
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers